Keros Therapeutics (KROS) Q1 2024 Earnings
KROS·Reported May 8, 2024·Before market open
Keros Therapeutics reported Q1 2024 revenue of $83.0K. Diluted EPS came in at $-1.21, beat the $-1.31 consensus by $0.10.
Revenue
$83.0K
Diluted EPS
$-1.21beat by $0.10
Consensus: $-1.31
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Keros Therapeutics's Q1 2024 earnings report.
Keros Therapeutics (KROS) reported Q1 2024 earnings on May 8, 2024 before market open.
Keros Therapeutics reported revenue of $83.0K and diluted EPS of $-1.21 for Q1 2024.
EPS beat the consensus estimate of $-1.31 by $0.10.
You can read the 10-Q periodic report (0001664710-24-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.